General
Pfizer’s COVID vaccine success is worth an extra $14 billion to the US pharma giant
The success of its COVID vaccine, and the challenges faced by some of its rivals, look set to earn US pharmaceutical giant Pfizer at least an extra $US11 billion ($14.2 billion) in revenue this year.
Key points:
- Pfizer has raised its 2021 revenue forecasts for COVID vaccine sales by 73 per cent
- Click here to view the original article.
Continue Reading
-
Noosa News22 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News23 hours agoMotorcyclist dies in crash with truck
-
Noosa News24 hours agoSomerville House investigating after teachers’ dossier on students leaked
-
Noosa News22 hours agoAustralia Post reintroduces weekend deliveries for Christmas parcel rush